喘息とCOPD治療薬市場レポート：2030年までの動向、予測、競合分析

喘息とCOPD治療薬の動向と予測

世界の喘息とCOPD治療薬市場は、2024年から2030年までのCAGRが4.3%で、2030年までに推定408億米ドルに達すると予測されます。この市場の主な促進要因は、呼吸器疾患の治療法の改善と新製品のイントロダクション、標的薬や生物製剤への関心の高まり、さらに都市化と高齢化の進行です。世界の喘息とCOPD治療薬市場の将来は、喘息とCOPD市場における機会によって有望視されています。

喘息とCOPD治療薬市場の洞察

Lucintelの予測では、予測期間中、配合剤が最大のセグメントであり続ける。

北米は、喘息の頻度の増加、製造業における重要なアクターの存在、タバコの喫煙習慣、同地域の確立されたインフラにより、予測期間中も最大地域であり続けるでしょう。

よくある質問

Q1.市場規模は？

A1.世界の喘息とCOPD治療薬市場は、2030年までに推定408億米ドルに達すると予想されています。

Q2.市場の成長予測は？

A2.世界の喘息とCOPD治療薬市場は、2024年から2030年にかけてCAGR 4.3%で成長すると予測されます。

Q3.市場の成長に影響を与える主な促進要因は？

A3.この市場の主な促進要因は、呼吸器疾患の治療法の改善と新製品の導入、標的薬や生物製剤への関心の高まり、さらに都市化と高齢化の進行です。

Q4.市場の主要セグメントは？

A4.世界の喘息とCOPD治療薬市場の将来は、喘息とCOPD市場に機会があり、有望です。

Q5.市場の主要企業は？

A5.主要な喘息とCOPD治療薬企業は以下の通りです。

• Novartis
• Glaxosmithkline
• Organon
• Boehringer Ingelheim International
• Abbott Laboratories
• AstraZeneca
• Sanofi
• Hoffmann-La Roche
• Vectura Group
• Teva Pharmaceutical Industries

Q6.今後、最大となる市場セグメントは？

A6.Lucintelは、予測期間中、配合剤が最大のセグメントであり続けると予測しています。

Q7.市場において、今後5年間に最大になると予想される地域は？

A7.北米は、喘息の頻度の増加、製造業における重要なアクターの存在、タバコの喫煙習慣、同地域の確立されたインフラにより、予測期間中も最大地域であり続ける。

Q8.レポートのカスタマイズは可能？

A8.はい、Lucintelは追加費用なしで10%のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界の喘息とCOPD治療薬市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界の喘息とCOPD治療薬市場の動向（2018～2023年）と予測（2024～2030年）
• 疾患別の世界の喘息とCOPD治療薬市場
  • 喘息
  • COPD
• 医薬品クラス別の世界の喘息とCOPD治療薬市場
  • 配合剤
  • 短時間作用性β2刺激薬
  • 長時間作用性β2刺激薬
  • ロイコトリエン拮抗薬
  • 抗コリン薬
  • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

• 地域別の世界の喘息とCOPD治療薬市場
• 北米の喘息とCOPD治療薬市場
• 欧州の喘息とCOPD治療薬市場
• アジア太平洋の喘息とCOPD治療薬市場
• その他地域の喘息とCOPD治療薬市場

第5章 競合の分析

• 製品ポートフォリオ分析
• 運用上の統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

• 成長機会分析
  • 疾患別の世界の喘息とCOPD治療薬市場の成長機会
  • 医薬品クラス別の世界の喘息とCOPD治療薬市場の成長機会
  • 地域別の世界の喘息とCOPD治療薬市場の成長機会
• 世界の喘息とCOPD治療薬市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界の喘息とCOPD治療薬市場の能力拡大
  • 世界の喘息とCOPD治療薬市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 有力企業の企業プロファイル

• Novartis
• Glaxosmithkline
• Organon
• Boehringer Ingelheim International
• Abbott Laboratories
• AstraZeneca
• Sanofi
• Hoffmann-La Roche
• Vectura Group
• Teva Pharmaceutical Industries

Asthma and COPD Drugs Trends and Forecast

The future of the global asthma and COPD drugs market looks promising with opportunities in the asthma and COPD markets. The global asthma and COPD drugs market is expected to reach an estimated $40.8 billion by 2030 with a CAGR of 4.3% from 2024 to 2030. The major drivers for this market are improvements in treating respiratory conditions and the introduction of new products, rising interest in targeted medicines and biologics, as well as, urbanization and an aging population on the rise.

A more than 150-page report is developed to help in your business decisions.

Asthma and COPD Drugs by Segment

The study includes a forecast for the global asthma and COPD drugs by diseases, medication class, and region.

Asthma and COPD Drugs Market by Diseases [Shipment Analysis by Value from 2018 to 2030]:

• Asthma
• COPD

Asthma and COPD Drugs Market by Medication Class [Shipment Analysis by Value from 2018 to 2030]:

• Combination Drugs
• Short Acting Beta Agonists
• Long Acting Beta Agonists
• Leukotriene Antagonists
• Anticholinergics
• Others

Asthma and COPD Drugs Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Asthma and COPD Drugs Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies asthma and COPD drugs companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the asthma and COPD drugs companies profiled in this report include-

• Novartis
• Glaxosmithkline
• Organon
• Boehringer Ingelheim International
• Abbott Laboratories
• AstraZeneca
• Sanofi
• Hoffmann-La Roche
• Vectura Group
• Teva Pharmaceutical Industries

Asthma and COPD Drugs Market Insights

Lucintel forecasts that combination drug will remain the largest segment over the forecast period.

North America will remain the largest region over the forecast period due to the increased frequency of asthma, the presence of significant actors in manufacturing, the tobacco smoking habit, and the region's well-established infrastructure.

Features of the Global Asthma and COPD Drugs Market

Market Size Estimates: Asthma and COPD drugs market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Asthma and COPD drugs market size by diseases, medication class, and region in terms of value ($B).

Regional Analysis: Asthma and COPD drugs market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different diseases, medication class, and regions for the asthma and COPD drugs market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the asthma and COPD drugs market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the asthma and COPD drugs market size?

Answer: The global asthma and COPD drugs market is expected to reach an estimated $40.8 billion by 2030.

Q2. What is the growth forecast for asthma and COPD drugs market?

Answer: The global asthma and COPD drugs market is expected to grow with a CAGR of 4.3% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the asthma and COPD drugs market?

Answer: The major drivers for this market are improvements in treating respiratory conditions and the introduction of new products, rising interest in targeted medicines and biologics, as well as, urbanization and an aging population on the rise.

Q4. What are the major segments for asthma and COPD drugs market?

Answer: The future of the global asthma and COPD drugs market looks promising with opportunities in the asthma and COPD markets.

Q5. Who are the key asthma and COPD drugs market companies?

Answer: Some of the key asthma and COPD drugs companies are as follows.

• Novartis
• Glaxosmithkline
• Organon
• Boehringer Ingelheim International
• Abbott Laboratories
• AstraZeneca
• Sanofi
• Hoffmann-La Roche
• Vectura Group
• Teva Pharmaceutical Industries

Q6. Which asthma and COPD drugs market segment will be the largest in future?

Answer: Lucintel forecasts that combination drug will remain the largest segment over the forecast period.

Q7. In asthma and COPD drugs market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to the increased frequency of asthma, the presence of significant actors in manufacturing, the tobacco smoking habit, and the region's well-established infrastructure.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the asthma and COPD drugs market by diseases (asthma and COPD), medication class (combination drugs, short acting beta agonists, long acting beta agonists, leukotriene antagonists, anticholinergics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Asthma and COPD Drugs Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Asthma and COPD Drugs Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Asthma and COPD Drugs Market by Diseases
  • 3.3.1: Asthma
  • 3.3.2: COPD
• 3.4: Global Asthma and COPD Drugs Market by Medication Class
  • 3.4.1: Combination Drugs
  • 3.4.2: Short Acting Beta Agonists
  • 3.4.3: Long Acting Beta Agonists
  • 3.4.4: Leukotriene Antagonists
  • 3.4.5: Anticholinergics
  • 3.4.6: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Asthma and COPD Drugs Market by Region
• 4.2: North American Asthma and COPD Drugs Market
  • 4.2.2: North American Asthma and COPD Drugs Market by Medication Class: Combination Drugs, Short Acting Beta Agonists, Long Acting Beta Agonists, Leukotriene Antagonists, Anticholinergics, and Others
• 4.3: European Asthma and COPD Drugs Market
  • 4.3.1: European Asthma and COPD Drugs Market by Diseases: Asthma and COPD
  • 4.3.2: European Asthma and COPD Drugs Market by Medication Class: Combination Drugs, Short Acting Beta Agonists, Long Acting Beta Agonists, Leukotriene Antagonists, Anticholinergics, and Others
• 4.4: APAC Asthma and COPD Drugs Market
  • 4.4.1: APAC Asthma and COPD Drugs Market by Diseases: Asthma and COPD
  • 4.4.2: APAC Asthma and COPD Drugs Market by Medication Class: Combination Drugs, Short Acting Beta Agonists, Long Acting Beta Agonists, Leukotriene Antagonists, Anticholinergics, and Others
• 4.5: ROW Asthma and COPD Drugs Market
  • 4.5.1: ROW Asthma and COPD Drugs Market by Diseases: Asthma and COPD
  • 4.5.2: ROW Asthma and COPD Drugs Market by Medication Class: Combination Drugs, Short Acting Beta Agonists, Long Acting Beta Agonists, Leukotriene Antagonists, Anticholinergics, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Asthma and COPD Drugs Market by Diseases
  • 6.1.2: Growth Opportunities for the Global Asthma and COPD Drugs Market by Medication Class
  • 6.1.3: Growth Opportunities for the Global Asthma and COPD Drugs Market by Region
• 6.2: Emerging Trends in the Global Asthma and COPD Drugs Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Asthma and COPD Drugs Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Asthma and COPD Drugs Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Novartis
• 7.2: Glaxosmithkline
• 7.3: Organon
• 7.4: Boehringer Ingelheim International
• 7.5: Abbott Laboratories
• 7.6: AstraZeneca
• 7.7: Sanofi
• 7.8: Hoffmann-La Roche
• 7.9: Vectura Group
• 7.10: Teva Pharmaceutical Industries